Progress in Cardiovascular Diseases
Volume 51, Issue 1 , Pages 74-88 , July 2008

Metabolic Reserve of the Heart: The Forgotten Link Between Contraction and Coronary Flow

  • Christos Kassiotis
    • ,
  • Mitra Rajabi
    • ,
  • Heinrich Taegtmeyer

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Heinrich Taegtmeyer, MD, DPhil, Division of Cardiology, Department of Internal Medicine, University of Texas Houston Medical School, 6431 Fannin, MSB 1.246, Houston, TX 77030.

References 

  1. Sonnenblick EH, Stam AC. Cardiac muscle: activation and contraction. Annu Rev Physiol. 1969;31:647–674
  2. Stam AC, Weglicki WB, Feldman JC, et al. Canine myocardial sarcolemma: its preparation and enzymic activity. J Mol Cell Cardiol. 1970;1:117–130
  3. Sonneblick EH, Ross J, Braunwald E. Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol. 1968;22:328–336
  4. Sonneblick EH, Parmley W, Parmley CW. The contractile state of the heart as expressed by force-velocity relations. Am J Cardiol. 1969;23:488–503
  5. Sonnenblick EH. Force-velocity relations in mammalian heart muscle. Am J Physiol. 1962;202:931–939
  6. Ross J, Covell JW, Sonnenblick EH, et al. Contractile state of the heart characterized by force-velocity relations in variably afterloaded and isovolumic beats. Circ Res. 1965;18:149–163
  7. Spann JF, Buccino RA, Sonnenblick EH, et al. Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure. Circ Res. 1967;21:341–354
  8. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol. 1994;19:57–116
  9. Cohn PF. Evaluation of inotropic contractile reserve in ischemic heart disease using postextrasystolic potentiation. Circulation. 1980;61:1071–1075
  10. Bonow RO. Contractile reserve and coronary blood flow reserve in collateral-dependent myocardium. J Am Coll Cardiol. 1999;33:705–707
  11. Gould KL, Kirkeeide RL, Buchi M. Coronary flow reserve as a physiologic measure of stenosis severity. J Am Coll Cardiol. 1990;15:459–474
  12. Galatro K, Chaudhry FA. Prognostic implications of myocardial contractile reserve in patients with ischemic cardiomyopathy. Echocardiography. 2000;17:61–67
  13. Taegtmeyer H, Golfman L, Sharma S, et al. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci. 2004;1015:202–213
  14. Newsholme EA, Leech L, Duester G: Fuel management. In: Keep on running: the science of training and performance. pp. 95-112. West Sussex, UK: John Wiley & Sons, Ltd., 1994 pp. 95-11.
  15. Duffield R, Dawson B, Goodman C. Energy system contribution to 100-m and 200-m track running events. J Sci Med Sport. 2004;7:302–313
  16. Johansen L, Quistorff B. 31P-MRS characterization of sprint and endurance trained athletes. Int J Sports Med. 2003;24:183–189
  17. Newsholme E, Leech L, Duester G. In: Filling the fuel tanks. In: Keep on running: the science of training and performance. West Sussex, UK: John Wiley & Sons, Ltd.; 1994;p. 70–94
  18. Krebs EG, Fischer EH. The phosphorylase b to a converting enzyme of rabbit skeletal muscle. Biochim Biophys Acta. 1956;20:150–157
  19. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol. 2000;278:H1345–H1351
  20. Callow M, Morton A, Guppy M. Marathon fatigue: the role of plasma fatty acids, muscle glycogen and blood glucose. Eur J Appl Physiol Occup Physiol. 1986;55:654–661
  21. Sjodin B, Svedenhag J. Applied physiology of marathon running. Sports Med. 1985;2:83–99
  22. van der Vusse GJ, Janssen GM, Coumans WA, et al. Effect of training and 15-, 25-, and 42-km contests on the skeletal muscle content of adenine and guanine nucleotides, creatine phosphate, and glycogen. Int J Sports Med. 1989;3(10 Suppl):S146–S152
  23. Sherman WM, Costill DL, Fink WJ, et al. Effect of a 42.2-km footrace and subsequent rest or exercise on muscle glycogen and enzymes. J Appl Physiol. 1983;55:1219–1224
  24. Borsheim E, Bahr R. Effect of exercise intensity, duration and mode on post-exercise oxygen consumption. Sports Med. 2003;33:1037–1060
  25. Maehlum S, Grandmontagne M, Newsholme EA, et al. Magnitude and duration of excess postexercise oxygen consumption in healthy young subjects. Metabolism. 1986;35:425–429
  26. Ren JM, Semenkovich CF, Gulve EA, et al. Exercise induces rapid increases in GLUT4 expression, glucose transport capacity, and insulin-stimulated glycogen storage in muscle. J Biol Chem. 1994;269:14396–14401
  27. Host HH, Hansen PA, Nolte LA, et al. Glycogen supercompensation masks the effect of a training-induced increase in GLUT-4 on muscle glucose transport. J Appl Physiol. 1998;85:133–138
  28. Garcia-Roves PM, Han DH, Song Z, et al. Prevention of glycogen supercompensation prolongs the increase in muscle GLUT4 after exercise. Am J Physiol Endocrinol Metab. 2003;285:E729–E736
  29. Pilegaard H, Keller C, Steensberg A, et al. Influence of pre-exercise muscle glycogen content on exercise-induced transcriptional regulation of metabolic genes. J Physiol. 2002;541:261–271
  30. Arany Z, He H, Lin J, et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005;1:259–271
  31. Pilegaard H, Osada T, Andersen LT, et al. Substrate availability and transcriptional regulation of metabolic genes in human skeletal muscle during recovery from exercise. Metabolism. 2005;54:1048–1055
  32. Johnson R, Walton J, Krebs H, et al. Metabolic fuels during and after severe exercise in athletes and non-athletes. Lancet. 1969;2:452–455
  33. Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator–activated receptor alpha. J Biol Chem. 1998;273:23786–23792
  34. Finck BN, Kelly DP. Peroxisome proliferator–activated receptor gamma coactivator–1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation. 2007;115:2540–2548
  35. Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets. 2006;7:1435–1441
  36. Dokken BB, Henriksen EJ. Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats. Am J Physiol Endocrinol Metab. 2006;291:E207–E213
  37. Henriksen EJ, Kinnick TR, Teachey MK, et al. Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab. 2003;284:E892–E900
  38. Sebastian D, Herrero L, Serra D, et al. Carnitine palmitoyltransferase I (Cpt I) overexpression protects L6e9 muscle cells from fatty acid–induced insulin resistance. Am J Physiol Endocrinol Metab. 2006;
  39. Perdomo G, Commerford SR, Richard AM, et al. Increased beta-oxidation in muscle cells enhances insulin-stimulated glucose metabolism and protects against fatty acid–induced insulin resistance despite intramyocellular lipid accumulation. J Biol Chem. 2004;279:27177–27186
  40. Fujii N, Jessen N, Goodyear LJ. AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab. 2006;291:E867–E877
  41. Kemppainen J, Tsuchida H, Stolen K, et al. Insulin signalling and resistance in patients with chronic heart failure. J Physiol. 2003;550:305–315
  42. Paternostro G, Camici PG, Lammertsma AA, et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest. 1996;98:2094–2099
  43. Dutka DP, Pitt M, Pagano D, et al. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol. 2006;48:2225–2231
  44. Iozzo P, Chareonthaitawee P, Dutka D, et al. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes. 2002;51:3020–3024
  45. Racker E. Energy cycles in health and disease. Curr Top Cell Regul. 1981;18:361–375
  46. Goodwin GW, Taylor CS, Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem. 1998;273:29530–29539
  47. Taegtmeyer H. Glycogen in the heart—an expanded view. J Mol Cell Cardiol. 2004;37:7–10
  48. Goodwin GW, Taegtmeyer H. Improved energy homeostasis of the heart in the metabolic state of exercise. Am J Physiol Heart Circ Physiol. 2000;279:H1490–H1501
  49. Nikoulina SE, Ciaraldi TP, Mudaliar S, et al. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes. 2002;51:2190–2198
  50. Sakamoto K, Arnolds DE, Ekberg I, et al. Exercise regulates Akt and glycogen synthase kinase–3 activities in human skeletal muscle. Biochem Biophys Res Commun. 2004;319:419–425
  51. Sakamoto K, Aschenbach WG, Hirshman MF, et al. Akt signaling in skeletal muscle: regulation by exercise and passive stretch. Am J Physiol Endocrinol Metab. 2003;285:E1081–E1088
  52. Condorelli G, Drusco A, Stassi G, et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A. 2002;99:12333–12338
  53. Horowitz JF, Leone TC, Feng W, et al. Effect of endurance training on lipid metabolism in women: a potential role for PPARalpha in the metabolic response to training. Am J Physiol Endocrinol Metab. 2000;279:E348–E355
  54. Baar K, Wende AR, Jones TE, et al. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J. 2002;16:1879–1886
  55. Pilegaard H, Saltin B, Neufer PD. Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. J Physiol. 2003;546:851–858
  56. Lehman JJ, Barger PM, Kovacs A, et al. Peroxisome proliferator–activated receptor gamma coactivator–1 promotes cardiac mitochondrial biogenesis. J Clin Invest. 2000;106:847–856
  57. Fisher DJ, Heymann MA, Rudolph AM. Myocardial oxygen and carbohydrate consumption in fetal lambs in utero and in adult sheep. Am J Physiol. 1980;238:H399–H405
  58. Bartelds B, Knoester H, Smid GB, et al. Perinatal changes in myocardial metabolism in lambs. Circulation. 2000;102:926–931
  59. Navaratnam V. Heart muscle: ultrastructural studies. New York: Cambridge University Press; 1987;
  60. Rolph T, Jones C, Parry D. Ultrastructural and enzymatic development of fetal guinea pig heart. Am J Physiol. 1982;243:H87–H93
  61. Fisher D, Heymann M, Rudolph A. Myocardial consumption of oxygen and carbohydrates in newborn sheep. Pediatr Res. 1981;15:843–846
  62. Pederson BA, Chen H, Schroeder JM, et al. Abnormal cardiac development in the absence of heart glycogen. Mol Cell Biol. 2004;24:7179–7187
  63. Lopaschuk GD, Spafford MA, Marsh DR. Glycolysis is predominant source of ATP production immediately after birth. Am J Physiol. 1991;261:H1698–H1705
  64. Lehman JJ, Kelly DP. Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin Exp Pharmacol Physiol. 2002;29:339–345
  65. Onay-Besikci A, Campbell FM, Hopkins TA, et al. Relative importance of malonyl CoA and carnitine in maturation of fatty acid oxidation in newborn rabbit heart. Am J Physiol Heart Circ Physiol. 2003;284:H283–H289
  66. Sack MN, Disch DL, Rockman HA, et al. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl Acad Sci U S A. 1997;94:6438–6443
  67. Depre C, Shipley GL, Chen W, et al. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med. 1998;4:1269–1275
  68. Razeghi P, Young ME, Alcorn JL, et al. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104:2923–2931
  69. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension. 1988;11:416–426
  70. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000;10:238–245
  71. Finck BN, Kelly DP. Peroxisome proliferator–activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol. 2002;34:1249–1257
  72. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116:615–622
  73. Barger PM, Brandt JM, Leone TC, et al. Deactivation of peroxisome proliferator–activated receptor–alpha during cardiac hypertrophic growth. J Clin Invest. 2000;105:1723–1730
  74. Disch DL, Rader TA, Cresci S, et al. Transcriptional control of a nuclear gene encoding a mitochondrial fatty acid oxidation enzyme in transgenic mice: role for nuclear receptors in cardiac and brown adipose expression. Mol Cell Biol. 1996;16:4043–4051
  75. Latronico MV, Costinean S, Lavitrano ML, et al. Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann N Y Acad Sci. 2004;1015:250–260
  76. Badorff C, Ruetten H, Mueller S, et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest. 2002;109:373–381
  77. Haq S, Choukroun G, Kang ZB, et al. Glycogen synthase kinase–3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol. 2000;151:117–130
  78. Michael A, Haq S, Chen X, et al. Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart. J Biol Chem. 2004;279:21383–21393
  79. Matsui T, Tao J, del Monte F, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001;104:330–335
  80. Lawrence JC, Roach PJ. New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes. 1997;46:541–547
  81. Luptak I, Balschi JA, Xing Y, et al. Decreased contractile and metabolic reserve in peroxisome proliferator–activated receptor–alpha–null hearts can be rescued by increasing glucose transport and utilization. Circulation. 2005;112:2339–2346
  82. Matsui T, Li L, Wu J, et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem. 2002;277:22896–22901
  83. Holubarsch C, Goulette RP, Litten RZ, et al. The economy of isometric force development, myosin isoenzyme pattern and myofibrillar ATPase activity in normal and hypothyroid rat myocardium. Circ Res. 1985;56:78–86
  84. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation. 2002;105:1861–1870
  85. Young ME, Yan J, Razeghi P, et al. Proposed regulation of gene expression by glucose in rodent heart. Gene Reg Sys Biol. 2007;1:251–262
  86. Young ME, Laws FA, Goodwin GW, et al. Reactivation of peroxisome proliferator–activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem. 2001;276:44390–44395
  87. Wambolt RB, Henning SL, English DR, et al. Regression of cardiac hypertrophy normalizes glucose metabolism and left ventricular function during reperfusion. J Mol Cell Cardiol. 1997;29:939–948
  88. Razeghi P, Young ME, Ying J, et al. Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology. 2002;97:203–209
  89. Sharma S, Ying J, Razeghi P, et al. Atrophic remodeling of the transplanted rat heart. Cardiology. 2006;105:128–136
  90. Semenza GL, Agani F, Iyer N, et al. Regulation of cardiovascular development and physiology by hypoxia-inducible factor 1. Ann N Y Acad Sci. 1999;30:262–268
  91. Huss JM, Levy FH, Kelly DP. Hypoxia inhibits the PPAR{alpha}/RXR gene regulatory pathway in cardiac myocytes. A mechanism for O{sub2}-dependent modulation of mitochondrial fatty acid oxidation. J Biol Chem. 2001;276:27605–27612
  92. Razeghi P, Young ME, Abbasi S, et al. Hypoxia in vivo decreases peroxisome proliferator–activated receptor alpha–regulated gene expression in rat heart. Biochem Biophys Res Commun. 2001;287:5–10
  93. Razeghi P, Essop MF, Huss JM, et al. Hypoxia-induced switches of myosin heavy chain iso-gene expression in rat heart. Biochem Biophys Res Commun. 2003;303:1024–1027
  94. Tong H, Imahashi K, Steenbergen C, et al. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase–dependent pathway is cardioprotective. Circ Res. 2002;90:377–379
  95. Nishihara M, Miura T, Miki T, et al. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol. 2006;291:H748–H755
  96. Kim SJ, Peppas A, Hong SK, et al. Persistent stunning induces myocardial hibernation and protection: flow/function and metabolic mechanisms. Circ Res. 2003;92:1233–1239
  97. Dewald O, Sharma S, Adrogue J, et al. Downregulation of peroxisome proliferator–activated receptor–alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation. 2005;112:407–415
  98. Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acids attenuate insulin regulation of 5'-AMP–activated protein kinase and insulin cardioprotection after ischemia. Circ Res. 2006;99:61–68
  99. Kantor PF, Dyck JR, Lopaschuk GD. Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci. 1999;318:3–14
  100. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–789
  101. Marsin AS, Bertrand L, Rider MH, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol. 2000;10:1247–1255
  102. Orchard CH. The role of the sarcoplasmic reticulum in the response of ferret and rat heart muscle to acidosis. J Physiol. 1987;384:431–449
  103. Bak M, Ingwall J. Acidosis during ischemia promotes adenosine triphosphate resynthesis in post-ischemic rat heart. J Clin Invest. 1994;93:40–49
  104. Sambandam N, Morabito D, Wagg C, et al. Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol. 2006;290:H87–H95
  105. Fallavollita JA, Malm BJ, Canty JMJ. Hibernating myocardium retains metabolic and contractile reserve despite regional reductions in flow, function, and oxygen consumption at rest. Circ Res. 2003;92:48–55
  106. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation. 2002;105:1727–1733
  107. Kliewer SA, Umesono K, Noonan DJ, et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992;358:771–774
  108. Motojima K, Passilly P, Peters JM, et al. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator–activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem. 1998;273:16710–16714
  109. Gulick T, Cresci S, Caira T, et al. The peroxisome proliferator–activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A. 1994;91:11012–11016
  110. Finck BN, Lehman JJ, Leone TC, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002;109:121–130
  111. Schmitz-Peiffer C. Signalling aspects of insulin resistance in skeletal muscle: mechanisms induced by lipid oversupply. Cell Signal. 2000;12:583–594
  112. Schmitz-Peiffer C, Craig DL, Biden TJ. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem. 1999;274:24202–24210
  113. Thompson AL, Cooney GJ. Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. Diabetes. 2000;49:1761–1765
  114. Wu P, Inskeep K, Bowker-Kinley MM, et al. Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. Diabetes. 1999;48:1593–1599
  115. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 1997;34:25–33
  116. Chen V, Ianuzzo C, Fong B, et al. The effects of acute and chronic diabetes on myocardial metabolism in rats. Diabetes. 1984;33:1078–1084
  117. Depre C, Young ME, Ying J, et al. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol. 2000;32:985–996
  118. Young ME, Patil S, Ying J, et al. Uncoupling protein 3 transcription is regulated by peroxisome proliferator–activated receptor (alpha) in the adult rodent heart. FASEB J. 2001;15:833–845
  119. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000;97:1784–1789
  120. Young ME, Guthrie PH, Razeghi P, et al. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes. 2002;51:2587–2595
  121. Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18:1692–1700
  122. Itani SI, Zhou Q, Pories WJ, et al. Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes. 2000;49:1353–1358
  123. Leichman JG, Aguilar D, King TM, et al. Association of plasma free fatty acids and left ventricular diastolic function in patients with clinically severe obesity. Am J Clin Nutr. 2006;84:336–341
  124. Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510–1515
  125. Roduit R, Morin J, Masse F, et al. Glucose down-regulates the expression of the peroxisome proliferator–activated receptor–alpha gene in the pancreatic beta-cell. J Biol Chem. 2000;275:35799–35806
  126. Gulick J, Subramaniam A, Neumann J, et al. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem. 1991;266:9180–9185
  127. Ojamaa K, Samarel AM, Klein I. Identification of a contractile-responsive element in the cardiac alpha-myosin heavy chain gene. J Biol Chem. 1995;270:31276–31281
  128. Golfman LS, Wilson CR, Sharma S, et al. Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab. 2005;289:E328–E336
  129. Sack MN, Rader TA, Park S, et al. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996;94:2837–2842
  130. Davila-Roman VG, Vedala G, Herrero P, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:271–277
  131. Blain JM, Schafer H, Siegel AL, et al. Studies on myocardial metabolism. VI. Myocardial metabolism in congestive failure. Am J Med. 1956;20:820–833
  132. Nemoto S, Razeghi P, Ishiyama M, et al. PPAR-gamma agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation. Am J Physiol Heart Circ Physiol. 2005;288:H77–H82

PII: S0033-0620(07)00114-4

doi: 10.1016/j.pcad.2007.11.005

Progress in Cardiovascular Diseases
Volume 51, Issue 1 , Pages 74-88 , July 2008

Article Tools

* Image Usage & Resolution